cancer stem cell-specific immunotherapy. Project Collaborations Industrial partners HYDRO ASA, Norway GEMVAX, Norway KAEL-GEMVAX, South-Korea, Norway DYNAL AS/INVITROGEN, Norway Sartorius CellGenix GmbH, Germany GE-Healthcare, Sweden Cellectics LVT, MI USA Immatics, Germany International partners Member Nordic Center of Excellence (NCOE) in cancer vaccines (partners at Karolinska, Herlev, Torino, Forli). Member ACT (Adoptive Cell Therapy) consortium (other members: Prof Per thor Straten, Center for Cancer Immunotherapy, Herlev, Prof. Ton Schumacher, Department of Immunology, Netherlands Cancer Institute, Amsterdam, the Netherlands, Prof. Niels Ødum Department of Biology, Division of Immunology, The Panum Institute, University of Copenhagen and Adaptimmune Ltd which is located in Oxfordshire, UK). Member of EU cancer vaccine/immunotherapy projects EUCAPS, ENACT and CHILDHOPE. Associated member of EU projects ALLOSTEM. Participation in international organizations such as EORTC, Nordic Lymphoma group etc. Prof Dolores Schendel, Institute of Molecular Immunology and Clinical Cooperation Group “Immune Monitoring,” Helmholtz Zentrum München. Optimization and GMP adaption of dendritic cell vaccines, maturation cocktails and fast DC. GMP production of mRNA for cancer vaccines against AML. Prof. Kris Thielemans, Department of Physiology and Immunology, Medical School of the Vrije Universiteit Brussel. Prof Stefaan van Gool, Klinikhoofd Kinder-hamato/neuro-oncologie, Laboratorium voor Experimentele Immunologie, Leuven. Clinical collaboration on development and clinical trial of DC vaccine for brain tumours. Prof. Malcolm Brenner, Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas. Clinical development of redirected T cells in solid tumours. Prof. Fred Fänderich, Klinik für angewandte Celltherapie, Universitetklinicum Schleswig-Holstein, Kiel. Joint protocol and GMP production of DC vaccines for treatment of brain tumours. Prof. Claudia Rossig, Universitetkinderklinik, Münster. Cellular based (T cells, NK cells and DC) therapy in children with neuroblastoma and Ewing sarcoma. Prof. Michael Nishimura, College of Medicine, Medical University of South Carolina. (Cancer Immunotherapy) References External links Cancer researchers 1943 births Living people 20th-century Norwegian scientists 21st-century Norwegian scientists People from Bærum